Editorial
Corneal Collagen Crosslinking in
the Management of Keratoconus
Tommy CY Chan, Alvin L
Young
Pak J Ophthalmol 2017, Vol. 33 No. 2
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . .
. . .
Keratoconus is a bilateral,
non-inflammatory corneal ectasia characterised by progressive corneal thinning and
bulging,
leading to progressive myopia, irregular astigmatism and corneal scarring1. The associated
irregular astigmatism and stromal
scarring have a
significant negative impact on the quality of life of affected patients. A
conservative approach in the management of keratoconus involves spectacles and
contact lenses. Surgical intervention including implantation of intra-corneal
ring segments or corneal transplantation may be necessary when conservative
means become intolerable or insufficient for visual
needs2. There are still controversies in relation to the diagnosis and management of keratoconus (KCN)3.
Corneal collagen cross linking (CXL) is
a treatment option for progressive keratoconus. It utilizes ultraviolet A irradiation
(UVA) and riboflavin to induce cross links within corneal stroma aiming to
increase the tensile strength and stability of the cornea. The first clinical
study was published in 2003 by Wollensak et al. reporting a reduction of the
maximum keratometry by 2 Diopters (D) and of refractive error by 1 D in 70% of
keratoconic eyes treated with CXL. It was also
noted that progression was halted in all of the treated eyes4.
It was not until recently in the USA, the Food and Drug Administration
approved the treatment CXL for KCN. However,
the precise
definition of progression remains
controversial.
Most studies offered CXL to eyes when there is an increase in maximum
keratometry (Kmax) of 1 Diopter or a change in either myopia or astigmatism of
1 D in 1 year5. Corneal thickness of less than
400μm, severe corneal scarring or ocular surface disease, prior herpetic
infection and pregnancy are contraindications for CXL.
The initial clinical studies to utilize
CXL in the treatment of progressive KCN employed
the Dresden protocol of 3 mW/cm2
irradiance for 30 minutes after corneal epithelial removal. It has been studied
in detail and shown good results clinically and on corneal topography.
Wittig-Silva et al. reported a change in Kmax by -1.03 D over 3 years, whereas
Hashemi et al. reported a change in Kmax by -0.16 D over 5 years6, 7. The key
limitation of this conservative procedure was that it took a long time for adequate treatment. To overcome this problem, accelerated
CXL using a higher
irradiance with a shortened treatment duration had emerged. According to the Bunsen-Roscoe
law of reciprocity, having a constant radiant exposure of 5.4 J/cm2,
a higher irradiance dose should theoretically give the same treatment response.
Comparative studies between conventional and various
accelerated CXL protocols revealed controversial results, given the great variability of the
protocols proposed8. Nevertheless, most studies reported the procedures to be safe to corneal endothelium.
To facilitate diffusion of riboflavin
into the
corneal stroma, epithelium-off CXL, which involves epithelial debridement, is
performed. This may lead to perioperative pain, abnormal wound healing and
rarely infectious keratitis9. Epithelium-on CXL was introduced as an attempt to circumvent the above. Various techniques have been employed to
enhance the penetration of riboflavin through intact corneal epithelium. These
include the use of topical chemical enhancers, mechanical microabrasions over the
corneal epithelium and iontophoresis10-12. However, clinical results with most
epithelium-on CXL were not as promising as epithelium-off CXL. It has been
demonstrated that a higher preoperative Kmax was associated with greater
corneal flattening after epithelium-on CXL in keratoconus10.
Intra-corneal ring segments and
photorefractive keratectomy have been combined with CXL aiming to provide rapid
visual improvement and stabilisation of KCN progression13,14. More
defined patient selection criteria, long-term
results and standardisation of treatment protocol are still needed to
support these combined treatments.
Current evidence supports the role of CXL in halting
keratoconus progression, albeit the relative lack of well conducted randomised
control studies15. Various modifications exist aiming to
improve the effective and safety profile of these treatments. However, controversies
remain regarding to the best timing of CXL, definition of disease progression,
repeated CXL treatment, method of riboflavin administration, use of alternative
chromophores, and treatment protocols. Individualisation of treatment protocol may provide
the best strategies for KCN patients. Further studies are warranted to explore these
fields in the future.
Authors
Affiliation
Dr. Tommy CY Chan
M
MedSc, FRCS
Department of Ophthalmology and Visual Sciences, The
Chinese University of Hong Kong, Hong Kong
Hong Kong Eye Hospital, Kowloon, Hong Kong
Dr. Alvin L Young
M MedSc
(Hons), FRCSIrel
Chief
of Service
Department
of Ophthalmology & Visual Sciences, Prince of Wales Hospital, The Chinese
University of Hong Kong; Shatin, Hong Kong
REFERENCES
1.
Jhanji V, Young AL. Keratoconus Citations: Battle of the Bulge. Asia Pac J Ophthalmol (Phila) 2014; 3 (2): 65-66.
2.
Parker JS, van Dijk K,
Melles GR. Treatment options for advanced keratoconus: A
review. Surv Ophthalmol. 2015; 60 (5):
459-480.
3.
Gomes JA, Tan D,
Rapuano CJ, Belin MW, Ambrosio R, Jr., Guell JL, Malecaze F, Nishida K, Sangwan
VS, Group of Panelists for the Global Delphi Panel of K, Ectatic
D. Global consensus on keratoconus and ectatic diseases. Cornea, 2015; 34 (4): 359-369.
4.
Wollensak G, Spoerl E,
Seiler T. Riboflavin/ ultraviolet-a-induced collagen
crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003; 135 (5): 620-627.
5.
Chan TC, Chow VW,
Jhanji V, Wong VW. Different Topographic Response Between
Mild to Moderate and Advanced Keratoconus After Accelerated Collagen
Cross-linking. Cornea, 2015; 34 (8): 922-927.
6.
Wittig-Silva C, Chan
E, Islam FM, Wu T, Whiting M, Snibson GR. A randomized,
controlled trial of corneal collagen cross-linking in progressive keratoconus:
three-year results. Ophthalmology,
2014; 121 (4): 812-821.
7.
Hashemi H, Seyedian
MA, Miraftab M, Fotouhi A, Asgari S. Corneal collagen
cross-linking with riboflavin and ultraviolet a irradiation for keratoconus:
long-term results. Ophthalmology,
2013; 120 (8): 1515-1520.
8.
Chow VW, Chan TC, Yu
M, Wong VW, Jhanji V. One-year outcomes of conventional and accelerated
collagen crosslinking in progressive keratoconus. Sci Rep. 2015; 514425.
9.
Abdelghaffar W,
Hantera M, Elsabagh H. Corneal collagen cross-linking: promises
and problems. Br J Ophthalmol. 2010; 94
(12): 1559-1560.
10. Chen S, Chan TC, Zhang J, Ding P, Chan JC,
Yu MC, Li Y, Jhanji V, Wang Q. Epithelium-on corneal collagen
crosslinking for management of advanced keratoconus. J Cataract Refract Surg. 2016; 42 (5): 738-749.
11. Rechichi M, Daya S, Scorcia V, Meduri A,
Scorcia G. Epithelial-disruption collagen crosslinking for
keratoconus: one-year results. J Cataract
Refract Surg. 2013; 39 (8): 1171-1178.
12. Buzzonetti L, Petrocelli G, Valente P,
Iarossi G, Ardia R, Petroni S. Iontophoretic transepithelial corneal
cross-linking to halt keratoconus in pediatric cases: 15-month follow-up. Cornea, 2015; 34 (5): 512-515.
13. Alessio G, L'Abbate M, Sborgia C, La Tegola
MG. Photorefractive keratectomy followed by cross-linking versus
cross-linking alone for management of progressive keratoconus: two-year
follow-up. Am J Ophthalmol. 2013; 155
(1): 54-65 e51.
14. Saelens IE, Bartels MC, Bleyen I, Van Rij
G. Refractive, topographic, and visual outcomes of same-day
corneal cross-linking with Ferrara intracorneal ring segments in patients with
progressive keratoconus. Cornea,
2011; 30 (12): 1406-1408.
15. Sykakis E, Karim R, Evans JR, Bunce C,
Amissah-Arthur KN, Patwary S, McDonnell PJ, Hamada S. Corneal collagen
cross-linking for treating keratoconus. Cochrane
Database Syst Rev. 2015 (3): CD010621.